Eli Lilly has selected Houston, Texas, as the location for a major new facility for active pharmaceutical ingredients (APIs) in the US that will support its fast-growing weight-loss business. The ...
uniQure's gene therapy for Huntington's has hit the mark in a clinical trial, raising hopes of the first treatment for the devastating neurodegenerative disease. Shares in the biotech rose sharply ...
President Donald Trump has given leading pharma manufacturers a 60-day deadline to come up with a most favoured nation (MFN) approach to drug pricing, or face consequences. Trump has sent letters to ...
Biologics have created revolutionary treatment options that have transformed the care journey for hundreds of millions of patients worldwide. In some cases, a painless injection is all that is now ...
Roche has dipped its toe in the M&A water with an agreement to buy US biotech 89bio and its late-stage candidate for metabolic dysfunction-associated steatohepatitis (MASH). The $14.50-per-share deal ...
While patients themselves may not know the source of their compounded drug, 503A vs 503B pharmacies have a direct effect on ...
A letter from HHS Secretary Robert F Kennedy Jr. and FDA Commissioner Martin Makary, in which they confirmed that the FDA is ...
All of the DTC channels offer discounts for people willing and able to pay for medicines with cash, and that also applies to ...
The drug – which will be sold in the US under the Inluriyo trade name – is only the second drug in the oral SERD category to ...
After all the threats, it seems President Trump's tariffs on pharmaceuticals are coming to fruition, and a lot sooner than ...
A big part of Biogen's efforts to defend its spinal muscular atrophy (SMA) business has been dealt a setback by the FDA, which declined to approve a high-dose version of its flagship Spinraza product.
Unresolved compliance issues at a manufacturing plant operated by Novo Nordisk have led to a complete response letter for Scholar Rock's lead drug for spinal muscular atrophy (SMA). The CRL is related ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback